Blueprint Medicines Makes Chris Varma Permanent CEO; Names Daniel Lynch Executive Chairman

Blueprint Medicines, a Cambridge, Mass.-based company that’s developing cancer therapies, has made Chris Varma, its founding president and an entrepreneur-in-residence at Third Rock Ventures, its permanent president and CEO. The company has also named Daniel Lynch as executive chairman of its board. Lynch spent nearly five years at ImClone Systems, including as CEO and CFO.

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget